ETERNITY INV (00764) plans to sell up to 20 million shares, raising approximately HK$19.6 million.
Eternal Strategy (00764) announced that on December 17, 2025, the company plans to offer up to 20 million shares, equivalent to approximately 4.96% of the issued share capital after the issuance and subscription of additional shares. The offer price for each share is 1.00 Hong Kong dollars. Assuming the maximum number of shares are allocated according to the subscription agreement, the total amount raised from the offering will be 20 million Hong Kong dollars, with a net amount of approximately 19.6 million Hong Kong dollars. The company intends to use the net proceeds to repay group debts and for general working capital.
ETERNITY INV (00764) announced on December 17, 2025, that the company plans to issue up to 20 million shares, equivalent to approximately 4.96% of the enlarged issued share capital of the company after the issuance. The issue price for the shares is HK$1.00 per share. Assuming the maximum number of shares are issued according to the agreement, the total proceeds from the share issue will be HK$20 million, with a net amount of approximately HK$19.6 million. The company plans to use the net proceeds to repay group debts and for general working capital.
Related Articles

LIANLIAN (02598) spent HKD 996,500 on December 17 to repurchase 158,500 shares.
.png)
Nebius (NBIS.US) launches the new generation AI cloud platform powered by NVIDIA Corporation's Blackwell Ultra chip to compete with CoreWeave.

BIOSTAR PHARM-B(02563): Yutidelong treatment of brain metastases in breast cancer, the first patient in the United States treated with key clinical research.
LIANLIAN (02598) spent HKD 996,500 on December 17 to repurchase 158,500 shares.

Nebius (NBIS.US) launches the new generation AI cloud platform powered by NVIDIA Corporation's Blackwell Ultra chip to compete with CoreWeave.
.png)
BIOSTAR PHARM-B(02563): Yutidelong treatment of brain metastases in breast cancer, the first patient in the United States treated with key clinical research.

RECOMMEND

Super Central Bank Week Arrives! Japan Leads With A Rate Hike As Developed Economies End The Rate‑Cut Cycle, Will The Fed Cut Alone Next Year?
16/12/2025

What Guidance Does The Economic Work Conference Offer For Cross‑Year Market Direction?
16/12/2025

Trade Surplus Tops One Trillion USD: New Challenges For China’s Foreign Trade | Instant Commentary
16/12/2025


